Detalhe da pesquisa
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
2.
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
Eur J Haematol
; 112(6): 957-963, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369814
3.
Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer.
J Cancer Res Clin Oncol
; 149(14): 12597-12604, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37452202
4.
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Clin Cancer Res
; 28(19): 4203-4211, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35594173